ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2020
Lowered endogenous mu-opioid receptor availability in subclinical depression and anxiety.
Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 1 synthesis or guideline pooled it, 88 citations in OpenAlex.
- Is the antidepressant efficacy of ketamine and esketamine mediated via opioid mechanisms?European psychiatry : the journal of the Association of European Psychiatrists · 2026Pooled it
- Contributions of dorsal medial prefrontal cortex GABAergic mu opioid receptors on acute restraint stress-induced anxiety-like behavior.Biology direct · 2026Article
- Endogenous opioid system modulates proximal and distal threat signals in the human brain.Molecular psychiatry · 2026Article
- Trajectories of late-life depression: insights from molecular imaging.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Review
- μ Opioid Modulation of Sensorimotor Functional Connectivity in Autism: Insights From a Pharmacological Neuroimaging Investigation Using Tianeptine.Biological psychiatry global open science · 2026Article
- OPRM1 gene polymorphism linked to anxiety in cancer-related pain patients: an observational study.Frontiers in pain research (Lausanne, Switzerland) · 2026Article
- New Antidepressant Development in the Treatment of Depression.Advances in experimental medicine and biology · 2026Review
- Innovative Approaches to Depression Therapy: The Antidepressant Efficacy and Mechanisms of General Anesthetics.Current neuropharmacology · 2026Review
- Updated Freudian drive theory: childhood trauma, epigenetics, serotonin and beta endorphin.Frontiers in psychiatry · 2026Article
- Anxiolytic and antidepressant effects of astaxanthin: behavioral and mechanistic insights in a rat model.Frontiers in pharmacology · 2026Article
- Neurotransmitter-based machine-learning model for distinguishing Alzheimer's disease and mild cognitive impairment.The Journal of international medical research · 2026Article
- Specific genetic and biological patterns underlying cortical morphological alterations in vascular cognitive impairment.Alzheimer's research & therapy · 2025Article
- Antidepressants and the endogenous opioid system.Biochemical pharmacology · 2025Review
- Molecular Mechanisms of Depression: The Interplay Between Genes and Receptors.International journal of molecular sciences · 2025Review
- Role of astrocytic mu-opioid receptors of the ventrolateral periaqueductal gray in modulating anxiety-like responses.Behavioral and brain functions : BBF · 2025Article
- Childhood family environment and μ-opioid receptor availability in vivo in adulthood.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025Article
- VTA µ-Opioidergic Neurons Facilitate Low Sociability in Protracted Opioid Abstinence.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2025Article
- Redefining Ketamine Pharmacology for Antidepressant Action: Synergistic NMDA and Opioid Receptor Interactions?The American journal of psychiatry · 2025Review
- Give me five! A modern perspective on addiction from the up-dated Freudian drive theory.Frontiers in psychiatry · 2025Article
- Potential common targets of music therapy intervention in neuropsychiatric disorders: the prefrontal cortex-hippocampus -amygdala circuit (a review).Frontiers in human neuroscience · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Major depressive disorder is associated with lowered mood, anxiety, anhedonia, sleep problems, and cognitive impairments. Many of these functions are regulated by μ-opioid receptor (MOR) system. Preclinical, in vivo, and post-mortem studies have however yielded inconclusive results regarding the role of the MOR in depression and anxiety. Moreover, it is not known whether alterations in MOR are already present in subclinical depression and anxiety. In a large-scale retrospective cross-sectional study we pooled data from 135 (113 males and 22 females) healthy subjects whose brain's MOR availability was measured with positron emission tomography (PET) using an agonist radioligand [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.